Lupin submits fresh studies for two products suspended by EMA

Posted by: Corporate Communications / VIVAN Life Sciences May 27, 2015

Drug firm LupinBSE 0.01 % has submitted fresh studies to the European Medicines Agency (EMA) for two products, which are among 700 generic drugs suspended by the health regulator due to flawed clinical trial data provided by GVK Bio.

“The company has successfully conducted the new bio equivalence (BE) studies for the said products and submitted the report in May 2015 for review by EMA,” Lupin Ltd said in a regulatory filing.

The Mumbai-based firm along with many other compa ..

Read more at:
http://economictimes.indiatimes.com/articleshow/47428166.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst